Advances in understanding and managing atopic dermatitis

F1000Research

Volumn 4, Issue , 2015, Pages

  Sidbury, Robert ^b   Barton, Michael ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPRURITIC AGENT; APREMILAST; CRISABOROLE; CT 327; DUPILUMAB; FILAGGRIN; OMALIZUMAB; PLACEBO; TEZEPELUMAB; THYMIC STROMAL LYMPHOPOIETIN; TRADIPITANT; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; ATOPIC DERMATITIS; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FLG GENE; GENOME SIZE; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; LOSS OF FUNCTION MUTATION; NONHUMAN; PATHOPHYSIOLOGY; PERMEABILITY BARRIER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN PRURITUS; SKIN SENSITIZATION; STRATUM CORNEUM; TIGHT JUNCTION; VITAMIN SUPPLEMENTATION;

EID: 84964545811     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.6972.1     Document Type: Article

References (44)

1. Boguniewicz M Leung DY: Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4-13. 20109729 10.1016/j.jaci.2009.11.027 2814072
2. Williams H Robertson C Stewart A: Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 Pt 1):125-38. 9893196 10.1016/S0091-6749(99)70536-1
3. Simpson EL Chalmers JR Hanifin JM: Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-23. 25282563 10.1016/j.jaci.2014.08.005 4180007 F1000 Recommendation
4. Ong PY Ohtake T Brandt C: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151-60. 12374875 10.1056/NEJMoa021481 F1000 Recommendation
5. Irvine AD McLean WH Leung DY: Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315-27. 21991953 10.1056/NEJMra1011040
6. Brown SJ Mclean WH: One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751-62. 22158554 10.1038/jid.2011.393 3378480 F1000 Recommendation
7. Rodríguez E Baurecht H Herberich E: Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol. 2009;123(6):1361-70.e7. 19501237 10.1016/j.jaci.2009.03.036 F1000 Recommendation
8. Leung DY Guttman-yassky E: Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769-79. 25282559 10.1016/j.jaci.2014.08.008 4186710
9. Margolis DV Apter AJ Gupta J: The persistence of atopic dermatitis and filaggrin ( FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol. 2012;130(4):912-7. 22951058 10.1016/j.jaci.2012.07.008 3462287 F1000 Recommendation
10. Bohme M Söderhäll C Kull I: Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization. J Allergy Clin Immunol. 2012;129(4):1153-5. 22360978 10.1016/j.jaci.2011.11.032 F1000 Recommendation
11. Thyssen JP Kezic S: Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792-9. 25065719 10.1016/j.jaci.2014.06.014
12. Broccardo CJ Mahaffey S Schwarz J: Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol. 2011;127(1):186-93, 193.e1-11. 21211653 10.1016/j.jaci.2010.10.033 3059191 F1000 Recommendation
13. Howell MD Kim BE Gao P: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7-12. 19720210 10.1016/j.jaci.2009.07.012 F1000 Recommendation
14. Boguniewicz M Leung DY: Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-46. 21682749 10.1111/j.1600-065X.2011.01027.x 3122139
15. Otsuka A Doi H Egawa G: Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol. 2014;133(1):139-46.e1-10. 24055295 10.1016/j.jaci.2013.07.027 F1000 Recommendation
16. Brough HA Liu AH Sicherer S: Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol. 2015;135(1):164-70. 25457149 10.1016/j.jaci.2014.10.007 4282723 F1000 Recommendation
17. Du Toit G Roberts G Sayre PH: Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803-13. 25705822 10.1056/NEJMoa1414850 4416404 F1000 Recommendation
18. Boyce JA Assa'ad A Burks AW: Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol. 2010;126(6):1105-18. 21134568 10.1016/j.jaci.2010.10.008 4241958
19. Hamilton JD Suárez-Fariũas M Dhingra N: Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293-300. 25482871 10.1016/j.jaci.2014.10.013 F1000 Recommendation
20. Beck LA Thaçi D Hamilton JD: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-9. 25006719 10.1056/NEJMoa1314768 F1000 Recommendation
21. Volf EM Au SC Dumont N: A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11(3):341-346. 22395585
22. Samrao A Berry TM Goreshi R: A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890-7. 22508772 10.1001/archdermatol.2012.812 3614494 F1000 Recommendation
23. Furue M Kitahara Y Akama H: Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014;41(7):577-85. 24942594 10.1111/1346-8138.12534 F1000 Recommendation
24. Moustafa F Feldman SR: A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608. 24852768
25. Kim DH Park KY Kim BJ: Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5):496-500. 23083013 10.1111/j.1365-2230.2012.04438.x F1000 Recommendation
26. El-Qutob D: Off-Label Uses of Omalizumab. Clin Rev Allergy Immunol. 2015;1-13. 26048266 10.1007/s12016-015-8490-y
27. Andreae DA Wang J: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Pediatrics. 2014;134(Suppl 3):S160. 25363953 10.1542/peds.2014-1817UU F1000 Recommendation
28. Hotze M Baurecht H Rodriguez E: Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 2014;69(1):132-5. 24111531 10.1111/all.12234 F1000 Recommendation
29. Peroni DG Piacentini GL Cametti E: Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. Br J Dermatol. 2011;164(5):1078-82. 21087229 10.1111/j.1365-2133.2010.10147.x F1000 Recommendation
30. Bäck O Blomquist HK Hernell O: Does vitamin D intake during infancy promote the development of atopic allergy? Acta Derm Venereol. 2009;89(1):28-32. 19197538 10.2340/00015555-0541
31. Oren E Banerji A Camargo CA Jr: Vitamin D and atopic disorders in an obese population screened for vitamin D deficiency. J Allergy Clin Immunol. 2008;121(2):533-4. 18177693 10.1016/j.jaci.2007.11.005 F1000 Recommendation
32. Sidbury R Sullivan AF Thadhani RI: Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. Br J Dermatol. 2008;159(1):245-7. 18489598 10.1111/j.1365-2133.2008.08601.x
33. Camargo CA Jr Ganmaa D Sidbury R: Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol. 2014;134(4):831-835.e1. 25282565 10.1016/j.jaci.2014.08.002
34. Amestejani M Salehi BS Vasigh M: Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study. J Drugs Dermatol. 2012;11(3):327-30. 22395583 F1000 Recommendation
35. Javanbakht MH Keshavarz SA Djalali M: Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. J Dermatolog Treat. 2011;22(3):144-50. 20653487 10.3109/09546630903578566 F1000 Recommendation
36. Chiu YE Havens PL Siegel DH: Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. J Am Acad Dermatol. 2013;69(1):40-6. 23415685 10.1016/j.jaad.2013.01.010 3661681 F1000 Recommendation
37. Gao PS Rafaels NM Mu D: Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol. 2010;125(6):1403-1407.e4. 20466416 10.1016/j.jaci.2010.03.016 2925504 F1000 Recommendation
38. Nakajima S Igyártó BZ Honda T: Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol. 2012;129(4):1048-55.e6. 22385635 10.1016/j.jaci.2012.01.063 4600611 F1000 Recommendation
39. Landheer J Giovannone B Mattson JD: Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in non-lesional skin of patients with atopic dermatitis. J Allergy Clin Immunol. 2013;132(5):1252-4. 24112829 10.1016/j.jaci.2013.07.051 F1000 Recommendation
40. Margolis DJ Kim B Apter AJ: Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis. JAMA Dermatol. 2014;150(3):254-9. 24401911 10.1001/jamadermatol.2013.7954 4414492 F1000 Recommendation
41. Gauvreau GM O'Byrne PM Boulet LP: Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102-10. 24846652 10.1056/NEJMoa1402895 F1000 Recommendation
42. Creabilis SA: Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Atopic Dermatitis. Luxembourg,2010. Reference Source
43. Roblin D Yosipovitch G Boyce B: Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015;95(5):542-8. 25594427 10.2340/00015555-2047 F1000 Recommendation
44. Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis. Washington DC,2015. Reference Source